Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
Status:
Withdrawn
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This purpose of this study is to evaluate the safety and effectiveness of a subcutaneous
(injection beneath the skin) form of methylnaltrexone in subjects who have cancer-related
pain and constipation from taking opioids. The length of participation will be up to 7 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.